Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis-Reference-Cited by-同舟云学术

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis

Published:2020-04-01 Issue:4 Volume:156 Page:393
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Atalay Selma¹,van den Reek Juul M. P. A.¹,den Broeder Alfons A.²,van Vugt Lieke J.¹,Otero Marisol E.¹,Njoo Marcellus D.³,Mommers Johannes M.⁴,Ossenkoppele Paul M.⁵,Koetsier Marjolein I.⁶,Berends Maartje A.⁷,van de Kerkhof Peter C. M.¹,Groenewoud Hans M. M.²,Kievit Wietske⁸,de Jong Elke M. G. J.¹

Affiliation:

1. Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands

2. Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands

3. Department of Dermatology, Ziekenhuis Groep Twente, Hengelo, the Netherlands

4. Department of Dermatology, Sint Anna Ziekenhuis, Geldrop, the Netherlands

5. Department of Dermatology, Ziekenhuis Groep Twente, Almelo, the Netherlands

6. Department of Dermatology, Gelre ziekenhuizen, Apeldoorn, the Netherlands

7. Department of Dermatology, Slingelandziekenhuis, Doetinchem, the Netherlands

8. Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2760342/jamadermatology_atalay_2020_oi_190078.pdf

Reference25 articles.

1. Psoriasis: from pathogenesis to targeted therapies.;Conrad;Clin Rev Allergy Immunol,2018

2. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.;Bongartz;JAMA,2006

3. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.;Papp;J Eur Acad Dermatol Venereol,2013

4. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.;Gordon;J Eur Acad Dermatol Venereol,2015

5. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an eight-year multicenter study;Chiu;J Am Acad Dermatol

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Considerations for paediatric patients;Australasian Journal of Dermatology;2024-05-13

2. Dose reduction of biologics in patients with plaque psoriasis: a review;Frontiers in Pharmacology;2024-03-28

3. Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study;British Journal of Dermatology;2024-02-17

4. Disease activity–guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study;Rheumatology;2024-02-12

5. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15